# Gem Pharmatech Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gem-pharmatech-co

- Industry: Biotechnology
- Headquarters: Nanjing, China
- Website: http://www.gempharmatech.com
- Total disclosed funding: $82M
- Latest round: Series B (Sep 11, 2020)
- Investors on record: 7

## About

Established in 2017 and based in Jiangsu, China, Gem Pharmatech Co.,Ltd is a biotechnology company that focuses on the research and development of humanization model and drug screening technology. In 2022, the company was listed on the Shanghai Stock Exchange. Its stock code is 688046. The company has several subsidiaries, including Chengdu Yaokang Biotechnology Co., Ltd. and Guangdong Yaokang Biotechnology Co., Ltd.

The company's main products include spotted mice, tool mice, germ-free mice and disease models. All protein-coding and non-coding genes that can be used in the design strategy of spotted mouse are CKO/KO modelling one by one. The company's products are used in basic research and new drug development fields such as gene function cognition, disease mechanism analysis, drug target discovery, drug efficacy screening and verification.

## Funding rounds

- Series B, Sep 11, 2020, $59M — Hong Shan, Morgan Stanley Private Equity Asia, YF Capital, TF Capital, GL Ventures
- Series A, Jun 3, 2019, $23M — CDH Investments, China National Traditional Chinese Medicine Investment

## Investors

- CDH Investments (https://capitalatlas.ai/funds/cdh-investments) — Series A
- China National Traditional Chinese Medicine Investment — Series A
- Hong Shan — Series B
- Morgan Stanley Private Equity Asia (https://capitalatlas.ai/funds/morgan-stanley-private-equity-asia) — Series B
- YF Capital (https://capitalatlas.ai/funds/yf-capital) — Series B
- TF Capital — Series B
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series B